David M. Denton

Chief Financial Officer, Executive Vice President (Principal Financial Officer), Pfizer

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

David M. Denton signed the annual report of Pfizer as Chief Financial Officer, Executive Vice President (Principal Financial Officer); the report was filed on February 26, 2026, the most recent filing in the record that ties David M. Denton to the seat.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Pfizer (PFE) Pharmaceutical Preparations	Chief Financial Officer, Executive Vice President (Principal Financial Officer)	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

February 26, 202610-K filed
David M. Denton signed the annual report of Pfizer on Form 10-K as Chief Financial Officer, Executive Vice President (Principal Financial Officer), filed February 26, 2026.
/S/ DAVID M. DENTON David M. Denton Chief Financial Officer, Executive Vice President (Principal Financial Officer)
[1] Annual report on Form 10-K by Pfizer, filed with the SEC on February 26, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Pfizer. U.S. Securities and Exchange Commission, EDGAR, filed February 26, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or David M. Denton wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.